Dr. Brian Crompton (at Dana Farber Cancer Institute) discusses the ongoing research behind liquid biopsy detection of Ewing sarcoma cells and ongoing efforts to leverage this technology to risk stratify patients at diagnosis, with the ultimate aim of changing the trajectory of cancer treatment on individual basis.
Ewing’s U: Liquid Biopsy ctDNA detection in Ewing sarcoma
Previous
Previous
SupraVax: Cleveland Clinic Ewing Sarcoma Vaccine Trial Update
Next
Next

